Frederick Howard

May 29, 2024 | ascopubs.org | Frederick Howard

Generative AI models such as OpenAI’s ChatGPT have been broadly utilized throughout the medical literature. Previous studies have found that AI can generate scientific abstracts which can be difficult to distinguish from the work of human authors.

Jul 27, 2023 | pubmed.ncbi.nlm.nih.gov | Frederick Howard |Daniel S Peiffer |Dezheng Huo

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

May 6, 2023 | nature.com | Jincong Q Freeman |Frederick Howard |Rita Nanda

AbstractOncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR.

Apr 14, 2023 | nature.com | Frederick Howard |James M. Dolezal |Andrew Srisuwananukorn |Rita Nanda |Charles M. Perou |Olufunmilayo I. Olopade | +2 more

AbstractGene expression-based recurrence assays are strongly recommended to guide the use of chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but such testing is expensive, can contribute to delays in care, and may not be available in low-resource settings. Here, we describe the training and independent validation of a deep learning model that predicts recurrence assay result and risk of recurrence using both digital histology and clinical risk factors.

Mar 30, 2023 | jamanetwork.com | Sarah Shubeck |Fangyuan Zhao |Frederick Howard |Olufunmilayo I. Olopade

Key PointsQuestion  Are there racial and ethnic differences in response to neoadjuvant chemotherapy of breast cancer that may have survival implications? Findings  In this cohort study of 107 207 patients with stage I to III breast cancer, significant racial and ethnic differences in pathologic complete response rates were observed. These racial and ethnic differences were subtype-specific and were found to account for a substantial portion of the identified survival disparity.